|
|
Article: Genentech.(Update)(increased risk of severe arterial thromboembolic events)(Brief Article)
- Article from:
- Medical Marketing & Media
- Article date:
- October 1, 2004
CopyrightCOPYRIGHT 2004 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genentech said there is evidence of an increased risk of severe arterial thromboembolic events related to the use of its Avastin (bevacizumab). In a letter released by the FDA in August, the company cited an ...
Related newspaper, magazine, and journal articles:
|
|
Article: Increased Risk of Breast Cancer with ...
Clinical Oncology Alert;
April 1, 2003 ;
700+ words
...Increased Risk of Breast Cancer with Estrogen-Progestin ... statistics, which amounted to an increased risk of 1.92 with 4-10 years of postmenopausal ... This produced a calculated overall increased risk of 1.09 that almost but not quite ...
|
|